Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Cell

Volumn 150, Issue 6, 2012, Pages 1107-1120

  Imielinski, Marcin ^a,b,c,d   Berger, Alice H ^a,d   Hammerman, Peter S ^a,d   Hernandez, Bryan ^a   Pugh, Trevor J ^a,d   Hodis, Eran ^a   Cho, Jeonghee ^e   Suh, James ^f   Capelletti, Marzia ^d   Sivachenko, Andrey ^a   Sougnez, Carrie ^a   Auclair, Daniel ^a   Lawrence, Michael S ^a   Stojanov, Petar ^a,d   Cibulskis, Kristian ^a   Choi, Kyusam ^e   De Waal, Luc ^a,d   Sharifnia, Tanaz ^a,d   Brooks, Angela ^a,d   Greulich, Heidi ^a,d   Banerji, Shantanu ^a,d   Zander, Thomas ^g,h   Seidel, Danila ^g   Leenders, Frauke ^g   Ansén, Sascha ^g   Ludwig, Corinna ^g   Engel Riedel, Walburga ^g   Stoelben, Erich ^g   Wolf, Jürgen ^g   Goparju, Chandra ^f   Thompson, Kristin ^a   Winckler, Wendy ^a   Kwiatkowski, David ^d   Johnson, Bruce E ^d   Jänne, Pasi A ^d   Miller, Vincent A ⁱ   Pao, William ^j   Travis, William D ⁱ   Pass, Harvey I ^f   Gabriel, Stacey B ^a   Lander, Eric S ^a,c,k   Thomas, Roman K ^g,h   Garraway, Levi A ^a,d   Getz, Gad ^a   Meyerson, Matthew ^a,c,d   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Samsung Medical Center   (South Korea)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLOGNE   (Germany)

^h MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j VANDERBILT INGRAM CANCER CENTER   (United States)

^k MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEOTIDE;

ADULT; AGED; ARTICLE; EXOME; FEMALE; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOME; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SMOKING;

EID: 84866410479     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.08.029     Document Type: Article

References (78)

1. I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, and S.R. Sunyaev A method and server for predicting damaging missense mutations Nat. Methods 7 2010 248 249
2. S. Banerji, K. Cibulskis, C. Rangel-Escareno, K.K. Brown, S.L. Carter, A.M. Frederick, M.S. Lawrence, A.Y. Sivachenko, C. Sougnez, and L. Zou Sequence analysis of mutations and translocations across breast cancer subtypes Nature 486 2012 405 409
3. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehár, G.V. Kryukov, and D. Sonkin The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
4. A.J. Bass, M.S. Lawrence, L.E. Brace, A.H. Ramos, Y. Drier, K. Cibulskis, C. Sougnez, D. Voet, G. Saksena, and A. Sivachenko Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion Nat. Genet. 43 2011 964 968
5. D.R. Bentley, S. Balasubramanian, H.P. Swerdlow, G.P. Smith, J. Milton, C.G. Brown, K.P. Hall, D.J. Evers, C.L. Barnes, and H.R. Bignell Accurate whole human genome sequencing using reversible terminator chemistry Nature 456 2008 53 59
6. M.F. Berger, M.S. Lawrence, F. Demichelis, Y. Drier, K. Cibulskis, A.Y. Sivachenko, A. Sboner, R. Esgueva, D. Pflueger, and C. Sougnez The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
7. M.F. Berger, E. Hodis, T.P. Heffernan, Y.L. Deribe, M.S. Lawrence, A. Protopopov, E. Ivanova, I.R. Watson, E. Nickerson, and P. Ghosh Melanoma genome sequencing reveals frequent PREX2 mutations Nature 485 2012 502 506
8. K. Bergethon, A.T. Shaw, S.H. Ou, R. Katayama, C.M. Lovly, N.T. McDonald, P.P. Massion, C. Siwak-Tapp, A. Gonzalez, and R. Fang ROS1 rearrangements define a unique molecular class of lung cancers J. Clin. Oncol. 30 2012 863 870
9. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
10. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 10.1038/nature11404 Published online September 9, 2012
11. M.A. Chapman, M.S. Lawrence, J.J. Keats, K. Cibulskis, C. Sougnez, A.C. Schinzel, C.L. Harview, J.P. Brunet, G.J. Ahmann, and M. Adli Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
12. J. Cho, S. Pastorino, Q. Zeng, X. Xu, W. Johnson, S. Vandenberg, R. Verhaak, A.D. Cherniack, H. Watanabe, and A. Dutt Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies Cancer Res. 71 2011 7587 7596
13. L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D.M. Muzny, and M.B. Morgan Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
14. A.J. Ekstrand, N. Sugawa, C.D. James, and V.P. Collins Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails Proc. Natl. Acad. Sci. USA 89 1992 4309 4313
15. S.J. Elsässer, C.D. Allis, and P.W. Lewis Cancer. New epigenetic drivers of cancers Science 331 2011 1145 1146
16. S. Fisher, A. Barry, J. Abreu, B. Minie, J. Nolan, T.M. Delorey, G. Young, T.J. Fennell, A. Allen, and L. Ambrogio A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries Genome Biol. 12 2011 R1
17. Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39 (Database issue), D945-D950. Published online October 15, 2010. http://dx.doi.org/10.1093/nar/gkq929
18. P.A. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, and M.R. Stratton A census of human cancer genes Nat. Rev. Cancer 4 2004 177 183
19. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, and P. Tarpey Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
20. T.A. Graubert, D. Shen, L. Ding, T. Okeyo-Owuor, C.L. Lunn, J. Shao, K. Krysiak, C.C. Harris, D.C. Koboldt, and D.E. Larson Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes Nat. Genet. 44 2012 53 57
21. L.M. Grovdal, E. Stang, A. Sorkin, and I.H. Madshus Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation Exp. Cell Res. 300 2004 388 395
22. P. Hainaut, and G.P. Pfeifer Patterns of p53 G - >T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke Carcinogenesis 22 2001 367 374
23. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
24. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
25. Y.K. Hashimoto, T. Satoh, M. Okamoto, and H. Takemori Importance of autophosphorylation at Ser186 in the A-loop of salt inducible kinase 1 for its sustained kinase activity J. Cell. Biochem. 104 2008 1724 1739
26. E. Hodis, I.R. Watson, G.V. Kryukov, S.T. Arold, M. Imielinski, J.P. Theurillat, E. Nickerson, D. Auclair, L. Li, and C. Place A landscape of driver mutations in melanoma Cell 150 2012 251 263
27. Y.S. Ju, W.C. Lee, J.Y. Shin, S. Lee, T. Bleazard, J.K. Won, Y.T. Kim, J.I. Kim, J.H. Kang, and J.S. Seo A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Genome Res. 22 2012 436 445
28. Z. Kan, B.S. Jaiswal, J. Stinson, V. Janakiraman, D. Bhatt, H.M. Stern, P. Yue, P.M. Haverty, R. Bourgon, and J. Zheng Diverse somatic mutation patterns and pathway alterations in human cancers Nature 466 2010 869 873
29. J.P. Koivunen, J. Kim, J. Lee, A.M. Rogers, J.O. Park, X. Zhao, K. Naoki, I. Okamoto, K. Nakagawa, and B.Y. Yeap Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients Br. J. Cancer 99 2008 245 252
30. T. Kosaka, Y. Yatabe, R. Onozato, H. Kuwano, and T. Mitsudomi Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J. Thorac. Oncol. 4 2009 22 29
31. M. Krzywinski, J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman, S.J. Jones, and M.A. Marra Circos: an information aesthetic for comparative genomics Genome Res. 19 2009 1639 1645
32. E.L. Kwak, Y.J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, R.G. Maki, S.H. Ou, B.J. Dezube, P.A. Jänne, and D.B. Costa Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 363 2010 1693 1703
33. W. Lee, Z. Jiang, J. Liu, P.M. Haverty, Y. Guan, J. Stinson, P. Yue, Y. Zhang, K.P. Pant, and D. Bhatt The mutation spectrum revealed by paired genome sequences from a lung cancer patient Nature 465 2010 473 477
34. P. Liu, C. Morrison, L. Wang, D. Xiong, P. Vedell, P. Cui, X. Hua, F. Ding, Y. Lu, and M. James Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing Carcinogenesis 33 2012 1270 1276
35. P. Medvedev, M. Stanciu, and M. Brudno Computational methods for discovering structural variation with next-generation sequencing Nat. Methods 6 Suppl 2009 S13 S20
36. J.D. Minna, and J.H. Schiller Lung Cancer A.S. Fauci, E. Braunwald, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, J. Loscalzo, Harrison's Principles of Internal Medicine 17th Edition 2008 McGraw-Hill New York 551 562
37. T. Mitsudomi, T. Oyama, T. Kusano, T. Osaki, R. Nakanishi, and T. Shirakusa Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer J. Natl. Cancer Inst. 85 1993 2018 2023
38. S.I. Nikolaev, D. Rimoldi, C. Iseli, A. Valsesia, D. Robyr, C. Gehrig, K. Harshman, M. Guipponi, O. Bukach, and V. Zoete Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma Nat. Genet. 44 2012 133 139
39. W. Pao, and J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. Rev. Cancer 10 2010 760 774
40. W. Pao, and K.E. Hutchinson Chipping away at the lung cancer genome Nat. Med. 18 2012 349 351
41. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, and L. Fulton EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. USA 101 2004 13306 13311
42. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris, and H.E. Varmus KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med. 2 2005 e17
43. L.R. Pearce, D. Komander, and D.R. Alessi The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 11 2010 9 22
44. G. Pines, P.H. Huang, Y. Zwang, F.M. White, and Y. Yarden EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism Oncogene 29 2010 5850 5860
45. M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J.M. Engles, W.H. Westra, J.G. Herman, and D. Sidransky Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung Cancer Res. 62 2002 3659 3662
46. B. Schuster-Böckler, and B. Lehner Chromatin organization is a major influence on regional mutation rates in human cancer cells Nature 488 2012 504 507
47. R.J. Slebos, R.H. Hruban, O. Dalesio, W.J. Mooi, G.J. Offerhaus, and S. Rodenhuis Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung J. Natl. Cancer Inst. 83 1991 1024 1027
48. N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, A. Sivachenko, G.V. Kryukov, M.S. Lawrence, C. Sougnez, and A. McKenna The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
49. K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, and H. Uehara RET, ROS1 and ALK fusions in lung cancer Nat. Med. 18 2012 378 381
50. H. Tanaka, K. Yanagisawa, K. Shinjo, A. Taguchi, K. Maeno, S. Tomida, Y. Shimada, H. Osada, T. Kosaka, and H. Matsubara Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1 Cancer Res. 67 2007 6007 6011
51. Y. Totoki, K. Tatsuno, S. Yamamoto, Y. Arai, F. Hosoda, S. Ishikawa, S. Tsutsumi, K. Sonoda, H. Totsuka, and T. Shirakihara High-resolution characterization of a hepatocellular carcinoma genome Nat. Genet. 43 2011 464 469
52. W.D. Travis Pathology of lung cancer Clin. Chest Med. 23 2002 65 81 viii
53. X. Wei, V. Walia, J.C. Lin, J.K. Teer, T.D. Prickett, J. Gartner, S. Davis, K. Stemke-Hale, M.A. Davies, J.E. Gershenwald NISC Comparative Sequencing Program Exome sequencing identifies GRIN2A as frequently mutated in melanoma Nat. Genet. 43 2011 442 446
54. B.A. Weir, M.S. Woo, G. Getz, S. Perner, L. Ding, R. Beroukhim, W.M. Lin, M.A. Province, A. Kraja, and L.A. Johnson Characterizing the cancer genome in lung adenocarcinoma Nature 450 2007 893 898
55. M. Wheeler, and J. Domin Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2 Mol. Cell. Biol. 21 2001 6660 6667
56. World Health Organization (2012). Cancer (http://www.who.int/cancer/en/).
57. K. Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata, R. Yamamoto, Y. Sato, A. Sato-Otsubo, A. Kon, and M. Nagasaki Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
58. Y. Yuza, K.A. Glatt, J. Jiang, H. Greulich, Y. Minami, M.S. Woo, T. Shimamura, G. Shapiro, J.C. Lee, and H. Ji Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors Cancer Biol. Ther. 6 2007 661 667
59. Z.J. Zang, I. Cutcutache, S.L. Poon, S.L. Zhang, J.R. McPherson, J. Tao, V. Rajasegaran, H.L. Heng, N. Deng, and A. Gan Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes Nat. Genet. 44 2012 570 574
60. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905.
61. Cairns, P., Mao, L., Merlo, A., Lee, D.J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J.E., and Sidransky, D. (1994). Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265, 415-417.
62. Capon, D.J., Seeburg, P.H., McGrath, J.P., Hayflick, J.S., Edman, U., Levinson, A.D., and Goeddel, D.V. (1983). Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304, 507-513.
63. Feinberg, A.P., Vogelstein, B., Droller, M.J., Baylin, S.B., and Nelkin, B.D. (1983). Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science 220, 1175-1177.
64. Greulich, H., Chen, T.H., Feng, W., Jänne, P.A., Alvarez, J.V., Zappaterra, M., Bulmer, S.E., Frank, D.A., Hahn, W.C., Sellers, W.R., and Meyerson, M. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313.
65. Jiang, J., Greulich, H., Jänne, P.A., Sellers, W.R., Meyerson, M., and Griffin, J.D. (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 65, 8968-8974.
66. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
67. Mitsudomi, T., Steinberg, S.M., Oie, H.K., Mulshine, J.L., Phelps, R., Viallet, J., Pass, H., Minna, J.D., and Gazdar, A.F. (1991). ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 51, 4999-5002.
68. Nagatake, M., Takagi, Y., Osada, H., Uchida, K., Mitsudomi, T., Saji, S., Shimokata, K., Takahashi, T., and Takahashi, T. (1996). Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56, 2718-2720.
69. Naoki, K., Chen, T.H., Richards, W.G., Sugarbaker, D.J., and Meyerson, M. (2002). Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62, 7001-7003.
70. Padmanabhan, B., Tong, K.I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.I., Kobayashi, A., Yokoyama, S., and Yamamoto, M. (2006). Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 21, 689-700.
71. Paez, J.G., Jänne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
72. Rodenhuis, S., van de Wetering, M.L., Mooi, W.J., Evers, S.G., van Zandwijk, N., and Bos, J.L. (1987). Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317, 929-935.
73. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554.
74. Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., Herman, J.G., Baylin, S.B., Sidransky, D., Gabrielson, E., et al. (2006). Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420.
75. Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526.
76. Sunaga, N., Kohno, T., Kolligs, F.T., Fearon, E.R., Saito, R., and Yokota, J. (2001). Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 30, 316-321.
77. Takahashi, T., Nau, M.M., Chiba, I., Birrer, M.J., Rosenberg, R.K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A.F., and Minna, J.D. (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491-494.
78. Wong, A.K., Shanahan, F., Chen, Y., Lian, L., Ha, P., Hendricks, K., Ghaffari, S., Iliev, D., Penn, B., Woodland, A.M., et al. (2000). BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 60, 6171-6177.